Reid et al. Safety of immune checkpoint inhibitor combo vs mono in pre-existing autoimmune disease. No significant difference. But 59% vs 32% for irAEs and 23% vs 10% for high grade irAEs @RheumNow #ACR22 Abstr#0757 https://t.co/UYhRM4xO9r https://t.co/r4NurxXzGZ

• Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Sin…

Bilal et al. Increased risk VTE in aPL+ SLE patients on estrogen vs progesterone contraceptive. All forms progesterone appears equally safe (differs ACR guidance which does not recommended IM or implant) @RheumNow #ACR22 Abstr#0943 https://t.co/HGuZJgaRZQ https://t.co/KrIaKaYNTy

• Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positiv…

7pm ET on 11/13, join our SLE panel. #ACR22 https://t.co/B8XdaJFLS2 https://t.co/kqJRI2QRms

• https://bit.ly/3tuxpH6

It's brilliant lab work @MayoClinic that had led the way for JAKi in GCA in clinical trials. A compelling bench-to-bedside story by @MdWarrington, Dr. Weyand, Dr. Koster and team, and definitely a space to watch #ACR22 @RheumNow https://t.co/2acKFrWOUF

"You won't find IgG4-RD anywhere [in the 2012 Chapel Hill nomenclature], but it is absolutely a vasculitis" -John Stone #ACR22 @RheumNow

LILAC study abstracts 0364 and 0365 SLE pts w/ joint and skin activity treated with BIIB059 had consistent improvements vs PBO. More to come! #ACR22 @RheumNow https://t.co/WPl3tol7v9 and https://t.co/8cyrI3W9rD https://t.co/5W4KMOHHEA

• Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Syste…
• Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participa…

Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help vasculopathy or #SSc renal crisis Rx is ACEi vs CCB in #Raynauds. 1 drug won’t be sufficient in complex diseases #13S114 #ACR22 #ACRBest ⁦@RheumNow⁩ #ClinicalPearl https://t.co/S8fHi7dFoD

MoA qu in GCA: Is one JAKi better? lab in tofa proof-of-concept in bari clinical trial in upa @MdWarrington: unclear if any diff clinically GM-CSF vs IL-17? Maria Cid: lots of redundancy in immune system blocking one pathway, escalation of another? we will see #ACR22 @RheumNow

Combined pulmonary HTN and ILD seen in 7% in large scleroderma database. Unsurprisingly, survival worse then PAH/ILD alone. HAQ also worse in this group. @RheumNow @earlyARA #ACR22 ABST1058 https://t.co/Jr58wVLC31 https://t.co/UCjKuJB1ev

• Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertensi…

Abs 0359 TULIP-1&2 data showed nearly 10% of anifrolumab-treated pts achieved remission, suggesting that DORIS response is attainable. #ACR22 @RheumNow https://t.co/laPwd0KpSa https://t.co/6LZ1WLrc97

• Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1…

Great scientific talk by John Stone, IgG4-RD should be a considered a variable-vessel disease, much like Behcet's and Cogan's syndrome I had not viewed it from that perspective; adding it to the list! Series of patietns w/coronary involvement esp interesting #ACR22 @RheumNow https://t.co/JUayLOTnSB

Slow pruning of Pulmonary arteries occurs way before we detect #PAH pulmonary hypertension in #scleroderma #SSc 13S114 lecture by Fred Wigley. Screen but need data re earlier Rx before Dx of PAH. May be assoc w anticentrome and +++ telangiectasia ⁦@RheumNow⁩ #ACR22 https://t.co/AgnIMYFKjB

#ACR22 Abstr#1464 Press Release #lupus. Should we worry of pts without nephritis & low grade proteinuria UPCR >0.2 & <0.5? A cohort study showed 50% progressed to =>0.5 at 2 yrs & 11% renal biopsy +ve. Important to monitor UPCR. Need biomarkers for this At-Risk @RheumNow #ACRBest https://t.co/eOODUynvP4

PCP docs managing AS? Abstract #0078 🧑‍⚕️ Assessed differences in management between PCP and rheumatologists 💉RHU prescribed more biologics 💊PCP prescribed more opiate and non-opiate pain medications 💊PCP did not often prescribe csDMARDs or biologics #ACR22 @RheumNow